• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor regarding: "Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem‑resistant Enterobacteriaceae infections: a systematic review and meta‑analysis".

作者信息

Babich Tanya, Leibovici Leonard, Daitch Vered

机构信息

Research Authority, Beilinson Hospital, Rabin Medical Center, 39 Jabotinski Road, Petah-Tikva, 49100, Israel.

Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

出版信息

Infection. 2025 May 21. doi: 10.1007/s15010-025-02563-3.

DOI:10.1007/s15010-025-02563-3
PMID:40397271
Abstract
摘要

相似文献

1
Letter to the editor regarding: "Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem‑resistant Enterobacteriaceae infections: a systematic review and meta‑analysis".致编辑的信：关于“头孢他啶-阿维巴坦与多粘菌素治疗碳青霉烯类耐药肠杆菌科细菌感染患者的系统评价和荟萃分析”
Infection. 2025 May 21. doi: 10.1007/s15010-025-02563-3.
2
Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.头孢他啶-阿维巴坦与多黏菌素治疗碳青霉烯类耐药肠杆菌科感染患者的比较：系统评价和荟萃分析。
Infection. 2024 Feb;52(1):19-28. doi: 10.1007/s15010-023-02108-6. Epub 2023 Oct 25.
3
Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis.头孢他啶-阿维巴坦与多黏菌素治疗碳青霉烯类耐药肠杆菌科感染的疗效和安全性：系统评价和荟萃分析。
BMJ Open. 2023 May 3;13(5):e070491. doi: 10.1136/bmjopen-2022-070491.
4
The Comparative Efficacy of Ceftazidime-Avibactam with or without Aztreonam vs Polymyxins for Carbapenem-resistant Enterobacteriaceae Infections: A Prospective Observational Cohort Study.头孢他啶-阿维巴坦联合或不联合氨曲南与多粘菌素治疗耐碳青霉烯类肠杆菌科细菌感染的疗效比较：一项前瞻性观察队列研究。
Indian J Crit Care Med. 2023 Dec;27(12):923-929. doi: 10.5005/jp-journals-10071-24577.
5
Ceftazidime-avibactam with or without Aztreonam vs Polymyxin-based Combination Therapy for Carbapenem-resistant Enterobacteriaceae: A Retrospective Analysis.头孢他啶-阿维巴坦联合或不联合氨曲南与基于多黏菌素的联合疗法治疗耐碳青霉烯类肠杆菌科细菌：一项回顾性分析
Indian J Crit Care Med. 2023 Jun;27(6):444-450. doi: 10.5005/jp-journals-10071-24481.
6
Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed production: a systematic review and meta-analysis.头孢他啶-阿维巴坦与氨曲南联合治疗疑似产碳青霉烯酶的耐碳青霉烯类肠杆菌血流感染：一项系统评价和荟萃分析。
Expert Rev Anti Infect Ther. 2024 Apr;22(4):203-209. doi: 10.1080/14787210.2024.2307912. Epub 2024 Feb 8.
7
Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.头孢他啶-阿维巴坦单药或与氨曲南联合多黏菌素治疗碳青霉烯类耐药肺炎克雷伯菌医院获得性感染（CAPRI 研究）：来自印度南部的回顾性队列研究。
Infection. 2024 Apr;52(2):429-437. doi: 10.1007/s15010-023-02094-9. Epub 2023 Sep 11.
8
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
9
Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.头孢他啶-阿维巴坦与黏菌素治疗碳青霉烯类耐药肠杆菌科菌血症的疗效比较。
Int J Infect Dis. 2021 Aug;109:1-7. doi: 10.1016/j.ijid.2021.05.079. Epub 2021 Jun 4.
10
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Infections.美罗培南-维巴坦与头孢他啶-阿维巴坦治疗碳青霉烯类耐药感染。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.02313-19.

本文引用的文献

1
Ceftazidime-avibactam versus polymyxins in treating patients with carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis.头孢他啶-阿维巴坦与多黏菌素治疗碳青霉烯类耐药肠杆菌科感染患者的比较：系统评价和荟萃分析。
Infection. 2024 Feb;52(1):19-28. doi: 10.1007/s15010-023-02108-6. Epub 2023 Oct 25.
2
Efficacy and safety of ceftazidime-avibactam versus polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infection: a systematic review and meta-analysis.头孢他啶-阿维巴坦与多黏菌素治疗碳青霉烯类耐药肠杆菌科感染的疗效和安全性：系统评价和荟萃分析。
BMJ Open. 2023 May 3;13(5):e070491. doi: 10.1136/bmjopen-2022-070491.
3
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
PRISMA 2020 声明：系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
4
Three risk of bias tools lead to opposite conclusions in observational research synthesis.三种偏倚风险工具在观察性研究综合分析中得出相反的结论。
J Clin Epidemiol. 2018 Sep;101:61-72. doi: 10.1016/j.jclinepi.2018.05.021. Epub 2018 Jun 2.
5
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.ROBINS-I：一种评估干预性非随机研究偏倚风险的工具。
BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919.